{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-299428","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2022-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.512863+00:00","generated_at":"2026-06-21T09:06:49.975747+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Invivyd appoints Jeremy Gowler as COO/CCO, promotes Pete Schmidt to CMO","bullets":["Jeremy Gowler appointed COO and CCO effective Dec 16, 2022; 20 years pharma commercial experience from Sandoz/Novartis.","Pete Schmidt promoted to CMO effective immediately; previously VP clinical research; CDO Hershberger departing but consulting.","Gowler receives $440K base salary, $150K signing bonus, target annual bonus 40%, and option grant of 625,000 shares.","Option vests 25% after 1 year then monthly over 3 years; severance includes 9-12 months salary depending on circumstances.","Company advancing pipeline of monoclonal antibodies against COVID-19 and other respiratory viruses."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-299428","json":"https://secwatch.observer/filing/0001193125-22-299428.json","markdown":"https://secwatch.observer/filing/0001193125-22-299428.md","text":"https://secwatch.observer/filing/0001193125-22-299428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522299428/0001193125-22-299428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522299428/d422123d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T09:06:49.975747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8dfae7ab3b","claim":"Jeremy Gowler was appointed as Chief Operating Officer and Chief Commercial Officer at Invivyd, Inc..","evidence_excerpt":"On December 6, 2022, Invivyd, Inc. (the “Company”) announced the appointment of Jeremy Gowler, age 46, as the Company’s Chief Operating Officer and Chief Commercial Officer, effective as of December 16, 2022 (the “Gowler Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522299428/0001193125-22-299428-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer and Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}